Eris Lifesciences Key Ratios
NSE: ERIS | BSE: 540596
₹1,258.90
As on 25-Sep-2026IST
Market cap
₹17,490 Cr
Revenue (TTM)
₹3,230 Cr
P/E Ratio
27.2
P/B Ratio
4.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 15.42 | 12.97 | 9.59 | 22.59 | 20.56 |
| EBIT | 9.88 | 8.71 | 16.84 | 24.70 | 16.16 |
| Net Profit | -49.44 | 20.68 | 69.34 | 19.69 | 11.96 |
| EPS | -49.47 | 18.59 | 64.38 | 18.46 | 11.23 |
| Book Value | -- | -- | 34.44 | 20.30 | 19.38 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 21.99 | 26.28 | 26.58 | 26.52 | 24.25 |
| Net Margin
| 12.26 | 20.92 | 20.60 | 20.57 | 12.87 |
| Return on equity
| 8.11 | 18.25 | 18.75 | 19.23 | 13.81 |
| Return on Capital
| 9.32 | 16.61 | -- | 14.47 | 13.59 |
| Return on Assets
| 4.66 | 11.41 | 9.26 | 9.18 | 5.48 |
| Debt to Equity (x)
| -- | -- | 0.24 | 0.59 | 0.85 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
14.47
|
13.59
|
12.37
|
17.30
|
|
Peer Median
|
--
|
19.34
|
21.76
|
21.89
|
--
|
ROE
18.75
Higher than Peers by 3.40
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
18.75
|
19.23
|
13.81
|
16.64
|
18.25
|
|
Peer Median
|
15.35
|
17.67
|
17.93
|
16.42
|
--
|
ROA
9.26
Lower than Peers by 1.08
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
9.26
|
9.18
|
5.48
|
7.72
|
13.40
|
|
Peer Median
|
10.35
|
9.88
|
12.81
|
12.32
|
--
|
EBIT Margin
26.58
Higher than Peers by 8.58
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
26.58
|
26.52
|
24.25
|
24.50
|
24.90
|
|
Peer Median
|
18.01
|
18.96
|
18.93
|
21.05
|
--
|
Net Margin
20.60
Higher than Peers by 6.15
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
20.60
|
20.57
|
12.87
|
19.53
|
22.06
|
|
Peer Median
|
14.45
|
13.32
|
14.94
|
15.51
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
28.49
|
23.21
|
27.41
|
27.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
9.59
Lower than Peers by 2.35
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
9.59
|
8.15
|
44.02
|
19.23
|
25.10
|
|
Peer Median
|
11.95
|
12.97
|
10.90
|
13.44
|
--
|
EBIT Growth
16.84
Lower than Peers by 4.75
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
16.84
|
18.26
|
42.54
|
17.31
|
-0.16
|
|
Peer Median
|
21.60
|
15.05
|
15.01
|
23.50
|
--
|
Net Profit Growth
69.34
Higher than Peers by 46.60
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
69.34
|
72.82
|
-5.65
|
6.14
|
-7.79
|
|
Peer Median
|
22.73
|
11.89
|
14.80
|
30.12
|
--
|
EPS Growth
64.38
Higher than Peers by 44.35
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
64.38
|
73.16
|
-10.39
|
2.58
|
-5.94
|
|
Peer Median
|
20.03
|
12.16
|
14.27
|
29.02
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
36.71
|
10.19
|
17.69
|
15.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.24
Higher than Peers by 0.24
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
0.24
|
0.59
|
0.85
|
1.06
|
0.38
|
|
Peer Median
|
0.00
|
0.05
|
0.06
|
0.03
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
0.12
|
0.14
|
0.51
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.74
Lower than Peers by 1.34
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
0.74
|
0.76
|
0.89
|
0.91
|
1.62
|
|
Peer Median
|
2.08
|
1.93
|
1.90
|
2.23
|
--
|
Quick Ratio
0.53
Lower than Peers by 1.01
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
0.53
|
0.56
|
0.67
|
0.84
|
1.41
|
|
Peer Median
|
1.54
|
1.52
|
1.46
|
1.59
|
--
|
Interest Coverage
4.45
Lower than Peers by 14.92
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
4.45
|
4.31
|
3.11
|
6.09
|
16.46
|
|
Peer Median
|
19.38
|
19.95
|
24.96
|
45.29
|
--
|
Operating Efficiency
Debtors to sales
21.07
Lower than Peers by 0.32
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
21.07
|
21.74
|
15.85
|
21.00
|
17.37
|
|
Peer Median
|
21.38
|
19.87
|
21.77
|
20.10
|
--
|
Asset Turnover
0.45
Lower than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
0.45
|
0.46
|
0.43
|
0.41
|
0.63
|
|
Peer Median
|
0.72
|
0.77
|
0.76
|
0.81
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
63.88
|
54.06
|
61.68
|
46.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
43.27
|
32.16
|
27.66
|
25.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
151.85
|
140.91
|
165.04
|
125.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
-44.70
|
-54.69
|
-75.70
|
-52.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
27.16
Lower than Peers by 8.05
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
27.16
|
29.02
|
54.83
|
29.18
|
20.36
|
|
Peer Median
|
35.22
|
35.33
|
26.81
|
39.85
|
--
|
Price / Book Value
4.34
Lower than Peers by 0.81
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
4.34
|
4.62
|
6.78
|
4.43
|
3.55
|
|
Peer Median
|
5.14
|
5.88
|
4.65
|
6.11
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
--
|
--
|
0.52
|
--
|
1.28
|
|
Peer Median
|
0.42
|
0.51
|
0.61
|
0.37
|
--
|
EV/EBITDA
17.20
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
17.20
|
17.93
|
20.75
|
18.29
|
15.61
|
|
Peer Median
|
--
|
30.09
|
27.02
|
34.57
|
--
|
Market Cap
17,490
Lower than Peers by 2,312
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Eris Lifesciences
|
17,490
|
17,980
|
19,293
|
11,440
|
7,779
|
|
Peer Median
|
19,802
|
17,907
|
20,914
|
25,297
|
--
|